Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C B Eap

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
Therapeutic Drug Monitoring|April 25, 2000
Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patientsC B Eap, S Bender, M Gastpar, et al.
The Pharmacogenomics Journal|June 2, 2010
β-Arrestin2 influences the response to methadone in opioid-dependent patientsB Oneda, S Crettol, M Bochud, et al.
Revue Medicale Suisse|February 2, 2013
[Psychiatry]P Conus, J-N Despland, F Herrera, et al.
Revue Medicale Suisse|February 7, 2008
[Addiction]J Besson, C B Eap, Y Khazaal, et al.
The Biochemical Journal|June 1, 1991
Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic miceW van Dijk, O Pos, M E van der Stelt, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population pharmacokinetics of imatinib and the role of alpha-acid glycoproteinN Widmer, L A Decosterd, C Csajka, et al.
Brain Research|March 1, 2000
Cytochrome P-450 activities in human and rat brain microsomesP Voirol, M Jonzier-Perey, F Porchet, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizersC B Eap, S Crettol, J-S Rougier, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
Therapeutic Drug Monitoring|April 25, 2000
Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patientsC B Eap, S Bender, M Gastpar, et al.
The Pharmacogenomics Journal|June 2, 2010
β-Arrestin2 influences the response to methadone in opioid-dependent patientsB Oneda, S Crettol, M Bochud, et al.
Revue Medicale Suisse|February 2, 2013
[Psychiatry]P Conus, J-N Despland, F Herrera, et al.
Revue Medicale Suisse|February 7, 2008
[Addiction]J Besson, C B Eap, Y Khazaal, et al.
The Biochemical Journal|June 1, 1991
Inflammation-induced changes in expression and glycosylation of genetic variants of alpha 1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic miceW van Dijk, O Pos, M E van der Stelt, et al.
British Journal of Pharmacology|July 2, 2010
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneC F Samer, Y Daali, M Wagner, et al.
British Journal of Pharmacology|July 2, 2010
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyC F Samer, Y Daali, M Wagner, et al.
British Journal of Clinical Pharmacology|July 18, 2006
Population pharmacokinetics of imatinib and the role of alpha-acid glycoproteinN Widmer, L A Decosterd, C Csajka, et al.
Brain Research|March 1, 2000
Cytochrome P-450 activities in human and rat brain microsomesP Voirol, M Jonzier-Perey, F Porchet, et al.
Clinical Pharmacology and Therapeutics|March 3, 2007
Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizersC B Eap, S Crettol, J-S Rougier, et al.
Pageof 10